Targets and strategies for vaccine development against dengue viruses

Dengue virus (DENV) is a global health threat causing about half of the worldwide population to be at risk of infection, especially the people living in tropical and subtropical area. Although the dengue disease caused by dengue virus (DENV) is asymptomatic and self-limiting in most people with firs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wen-Hung Wang, Aspiro Nayim Urbina, Chih-Yen Lin, Zih-Syuan Yang, Wanchai Assavalapsakul, Arunee Thitithanyanont, Po-Liang Lu, Yen-Hsu Chen, Sheng-Fan Wang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Dengue virus Dengue vaccine Live-attenuated virus Inactivated virus DNA vaccine Subunit vaccine Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4b82ac87f0794d5397fcf64639058fce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b82ac87f0794d5397fcf64639058fce
record_format	dspace
spelling	oai:doaj.org-article:4b82ac87f0794d5397fcf64639058fce2021-11-14T04:29:25ZTargets and strategies for vaccine development against dengue viruses0753-332210.1016/j.biopha.2021.112304https://doaj.org/article/4b82ac87f0794d5397fcf64639058fce2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S075333222101088Xhttps://doaj.org/toc/0753-3322Dengue virus (DENV) is a global health threat causing about half of the worldwide population to be at risk of infection, especially the people living in tropical and subtropical area. Although the dengue disease caused by dengue virus (DENV) is asymptomatic and self-limiting in most people with first infection, increased severe dengue symptoms may be observed in people with heterotypic secondary DENV infection. Since there is a lack of specific antiviral medication, the development of dengue vaccines is critical in the prevention and control this disease. Several targets and strategies in the development of dengue vaccine have been demonstrated. Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developed by Sanofi Pasteur, has been licensed and approved for clinical use in some countries. However, this vaccine has demonstrated low efficacy in children and dengue-naïve individuals and also increases the risk of severe dengue in young vaccinated recipients. Accordingly, many novel strategies for the dengue vaccine are under investigation and development. Here, we conducted a systemic literature review according to PRISMA guidelines to give a concise overview of various aspects of the vaccine development process against DENVs, mainly targeting five potential strategies including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral-vector vaccine, and DNA vaccine. This study offers the comprehensive view of updated information and current progression of immunogen selection as well as strategies of vaccine development against DENVs.Wen-Hung WangAspiro Nayim UrbinaChih-Yen LinZih-Syuan YangWanchai AssavalapsakulArunee ThitithanyanontPo-Liang LuYen-Hsu ChenSheng-Fan WangElsevierarticleDengue virusDengue vaccineLive-attenuated virusInactivated virusDNA vaccineSubunit vaccineTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112304- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dengue virus Dengue vaccine Live-attenuated virus Inactivated virus DNA vaccine Subunit vaccine Therapeutics. Pharmacology RM1-950
spellingShingle	Dengue virus Dengue vaccine Live-attenuated virus Inactivated virus DNA vaccine Subunit vaccine Therapeutics. Pharmacology RM1-950 Wen-Hung Wang Aspiro Nayim Urbina Chih-Yen Lin Zih-Syuan Yang Wanchai Assavalapsakul Arunee Thitithanyanont Po-Liang Lu Yen-Hsu Chen Sheng-Fan Wang Targets and strategies for vaccine development against dengue viruses
description	Dengue virus (DENV) is a global health threat causing about half of the worldwide population to be at risk of infection, especially the people living in tropical and subtropical area. Although the dengue disease caused by dengue virus (DENV) is asymptomatic and self-limiting in most people with first infection, increased severe dengue symptoms may be observed in people with heterotypic secondary DENV infection. Since there is a lack of specific antiviral medication, the development of dengue vaccines is critical in the prevention and control this disease. Several targets and strategies in the development of dengue vaccine have been demonstrated. Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developed by Sanofi Pasteur, has been licensed and approved for clinical use in some countries. However, this vaccine has demonstrated low efficacy in children and dengue-naïve individuals and also increases the risk of severe dengue in young vaccinated recipients. Accordingly, many novel strategies for the dengue vaccine are under investigation and development. Here, we conducted a systemic literature review according to PRISMA guidelines to give a concise overview of various aspects of the vaccine development process against DENVs, mainly targeting five potential strategies including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral-vector vaccine, and DNA vaccine. This study offers the comprehensive view of updated information and current progression of immunogen selection as well as strategies of vaccine development against DENVs.
format	article
author	Wen-Hung Wang Aspiro Nayim Urbina Chih-Yen Lin Zih-Syuan Yang Wanchai Assavalapsakul Arunee Thitithanyanont Po-Liang Lu Yen-Hsu Chen Sheng-Fan Wang
author_facet	Wen-Hung Wang Aspiro Nayim Urbina Chih-Yen Lin Zih-Syuan Yang Wanchai Assavalapsakul Arunee Thitithanyanont Po-Liang Lu Yen-Hsu Chen Sheng-Fan Wang
author_sort	Wen-Hung Wang
title	Targets and strategies for vaccine development against dengue viruses
title_short	Targets and strategies for vaccine development against dengue viruses
title_full	Targets and strategies for vaccine development against dengue viruses
title_fullStr	Targets and strategies for vaccine development against dengue viruses
title_full_unstemmed	Targets and strategies for vaccine development against dengue viruses
title_sort	targets and strategies for vaccine development against dengue viruses
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/4b82ac87f0794d5397fcf64639058fce
work_keys_str_mv	AT wenhungwang targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT aspironayimurbina targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT chihyenlin targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT zihsyuanyang targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT wanchaiassavalapsakul targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT aruneethitithanyanont targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT polianglu targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT yenhsuchen targetsandstrategiesforvaccinedevelopmentagainstdengueviruses AT shengfanwang targetsandstrategiesforvaccinedevelopmentagainstdengueviruses
_version_	1718430010389299200

Targets and strategies for vaccine development against dengue viruses

Ejemplares similares